Current State-of-the-Art Therapy for Malignant Pleural Mesothelioma and Future Options Centered on Immunotherapy
Susana Cedres, Augusto Valdivia, Patricia Iranzo, Ana Callejo, Nuria Pardo, Alejandro Navarro, Alex Martinez-Marti, Juan David Assaf-Pastrana, Enriqueta Felip, Pilar Garrido, Taketo Yamada · 2023
Read Current State-of-the-Art Therapy for Malignant Pleural Mesothelioma and Future Options Centered on Immunotherapy by Susana Cedres, Augusto Valdivia, Patricia Iranzo, Ana Callejo, Nuria Pardo, Alejandro Navarro, Alex Martinez-Marti, Juan David Assaf-Pastrana, Enriqueta Felip, Pilar Garrido, Taketo Yamada (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10741743.txt.
Description
Susana Cedres and co-authors review current therapy for malignant pleural mesothelioma, a fast-growing cancer tied to asbestos. With no treatment, patients often live only a few months. Standard care long rested on platinum chemotherapy with an antifolate drug, and adding bevacizumab stretched survival by a short margin.
A first-line immunotherapy pairing then changed the field: nivolumab plus ipilimumab beat the older chemotherapy on overall survival in a major trial. Regulators in the United States and Europe approved the pairing. The pairing is now a standard first treatment in many countries. Not every patient gains from it, though. The review covers biomarkers that may flag likely responders and notes that the cancer has low mutation load, which makes it hard to predict who will respond.
Catalog record
| CREATOR | Susana Cedres, Augusto Valdivia, Patricia Iranzo, Ana Callejo, Nuria Pardo, Alejandro Navarro, Alex Martinez-Marti, Juan David Assaf-Pastrana, Enriqueta Felip, Pilar Garrido, Taketo Yamada |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 46 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |